Investors on the hunt for entry points and hidden gems often have their eyes set on quality stocks hovering around their 52-week low levels. These junctures can present a unique window of opportunity in the capital market.
In focus are three well-established companies with market capitalizations each hovering around the $35 billion mark. These are: Starbucks Corp SBUX, Gilead Sciences GILD, and Ambev SA ABEV.
Starbucks: A Brew of Investment Potential
At approximately $86.83 per share, the stock of this coffee giant may signify a ‘buy-the-dip’ opportunity. With a market cap exceeding $98 billion, the Seattle-based company’s shares boast an average three-month trading volume of 8.49 million.
Additionally, investors in Starbucks can enjoy a dividend yield of 2.63%.
Analyst ratings from Wells Fargo, TD Cowen, and TD Cowen penned on April 1, April 1, and March 19, 2024, respectively, have set an average price target of $102.33 for Starbucks Corp. This suggests a promising 17.23% potential upside based on the insights of these analysts.
Gilead Sciences: A Prescription for Recovery?
Priced around $69.32, the biopharma stock sits close to its 52-week lows. Gilead Sciences has garnered acclaim for its development of antiretroviral drugs in the HIV/AIDS treatment landscape, including notable medications like Truvada, Atripla, and Descovy.
Offering investors a robust dividend yield of 4.43%, Gilead stock presents an enticing opportunity.
Recent analyst reviews from Wells Fargo, Mizuho, and Truist Securities have cumulatively set an average price target of $83.33 for Gilead stock, hinting at a potential 20.16% upside for the company.
Ambev: Pouring Out Lucrative Returns?
Famed for its beer brands such as Skol, Brahma, Antarctica, and Budweiser, Ambev SA is trading at $2.40, hovering near its 52-week low of $2.36. The stock’s appeal is further enhanced by a generous dividend yield of 6.26%.
Barclays, Jefferies, and Bernstein have each issued their latest analyst ratings on March 4, 2024, Nov. 22, 2023, and May 24, 2023, respectively, establishing a consensus price target of $3.2 for Ambev stock. Collectively, these assessments suggest an impressive 32.51% upside potential for the company.
These findings underscore the potential for these quality stocks to offer attractive investment prospects, potentially delivering favorable returns for investors in the months ahead.
